Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 8,161 matching trials from the live ClinicalTrials.gov search.
Filters: Phoenix, Arizona Clear all
Completed Phase 2 Interventional

Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS)

NCT01708707
View directory record Official record
Conditions
Neonatal Abstinence Syndrome, Neonatal Withdrawal Syndrome
Interventions
Buprenorphine, Morphine Sulfate
Drug
Lead sponsor
Pediatrix
Other
Eligibility
Up to 1 Year
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Nov 4, 2026, 7:03 AM EST
Terminated Phase 1 Interventional

A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

NCT05226507
View directory record Official record
Conditions
Advanced Solid Tumor, Ovarian Cancer, Ovarian Clear Cell Carcinoma, Ovarian Clear Cell Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Endometrioid Tumor, ARID1A Gene Mutation
Interventions
NXP800
Drug
Lead sponsor
Nuvectis Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
19
States / cities
Phoenix, Arizona • La Jolla, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Nov 4, 2026, 7:03 AM EST
Completed Phase 3 Interventional

Efficacy & Safety of Resatorvid in Adults With Severe Sepsis

NCT00143611
View directory record Official record
Conditions
Sepsis
Interventions
Resatorvid, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
49
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Nov 4, 2026, 7:03 AM EST
Completed Phase 1 Interventional

A Study of Guselkumab in Participants With Familial Adenomatous Polyposis

NCT03649971
View directory record Official record
Conditions
Adenomatous Polyposis Coli
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
18
States / cities
Phoenix, Arizona • Duarte, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Nov 4, 2026, 7:03 AM EST
Completed Phase 3 Interventional Results available

A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes

NCT00838916
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
albiglutide, insulin glargine
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
779 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
314
States / cities
Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 252 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Nov 4, 2026, 7:03 AM EST
Terminated Phase 2 Interventional

A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery

NCT05814016
View directory record Official record
Conditions
Sleep Apnea
Interventions
Danavorexton, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
30 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
19
States / cities
Sheffield, Alabama • Phoenix, Arizona • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Nov 4, 2026, 7:03 AM EST
Completed Phase 2 Interventional

Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis

NCT01055106
View directory record Official record
Conditions
Vaginosis, Bacterial, Vaginal Infection
Interventions
GW05, Metronidazole
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
20
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2011 · Synced Nov 4, 2026, 7:03 AM EST
Completed Phase 3 Interventional Results available

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

NCT00412984
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
warfarin, apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
20,976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
284
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 206 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Nov 4, 2026, 7:03 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

The weWomen and ourCircle Intervention for Immigrant, Refugee and Indigenous Women

NCT03265847
View directory record Official record
Conditions
Violence, Domestic, Violence-Related Symptom
Interventions
Culturally-tailored Safety Planning
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
688 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Nov 4, 2026, 7:03 AM EST
Completed No phase listed Observational

Home-based Remote Digital Monitoring to Assess ALS Progression (Track ALS)

NCT05276349
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Not listed
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Phoenix, Arizona • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Nov 4, 2026, 7:03 AM EST
Terminated No phase listed Observational Accepts healthy volunteers

Reference Values and Determinants of Hydration in Children 3-13 y

NCT02937038
View directory record Official record
Conditions
Dehydration
Interventions
Not listed
Lead sponsor
Arizona State University
Other
Eligibility
3 Years to 13 Years
Enrollment
1,454 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Nov 4, 2026, 7:03 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants

NCT04382326
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
1,997 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
105
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Nov 4, 2026, 7:03 AM EST
Completed Phase 2 Interventional Results available

Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT01342926
View directory record Official record
Conditions
Atrophy, Geographic
Interventions
GSK933776, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
55 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
40
States / cities
Phoenix, Arizona • Arcadia, California • Irvine, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 5, 2017 · Synced Nov 4, 2026, 7:03 AM EST
Completed Phase 2 Interventional

Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy

NCT00004985
View directory record Official record
Conditions
HIV Infections
Interventions
Capravirine, Nelfinavir mesylate
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
33
States / cities
Phoenix, Arizona • Beverly Hills, California • Palm Springs, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 4, 2026, 7:03 AM EST
Completed Phase 3 Interventional

Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia

NCT05838625
View directory record Official record
Conditions
Schizophrenia
Interventions
CT-155, Digital Control
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
54
States / cities
Chandler, Arizona • Phoenix, Arizona • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Nov 4, 2026, 7:03 AM EST
Completed Phase 2 Interventional Results available

Odiparcil For The Prevention Of Venous Thromboembolism

NCT00244725
View directory record Official record
Conditions
Deep Vein Thrombosis, Fibrillation, Atrial, Venous Thromboembolism, Pulmonary Embolism
Interventions
Odiparcil, Warfarin, Coumadin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
35 Years and older
Enrollment
961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
46
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Nov 4, 2026, 7:03 AM EST
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

NCT00369317
View directory record Official record
Conditions
Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Childhood Myelodysplastic Syndromes, de Novo Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions
asparaginase, daunorubicin hydrochloride, cytarabine, thioguanine, etoposide, laboratory biomarker analysis
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 4 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2021
U.S. locations
88
States / cities
Phoenix, Arizona • Downey, California • Long Beach, California + 73 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Nov 4, 2026, 7:03 AM EST
Completed Phase 3 Interventional Results available

A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT03573908
View directory record Official record
Conditions
Irritable Bowel Syndrome Characterized by Constipation
Interventions
Linaclotide, Placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
79
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Nov 4, 2026, 7:03 AM EST
Completed No phase listed Observational

LONGEVITY Study. Evaluation of the Device and Battery Longevity of Boston Scientific Market-released ICD and CRT-D Devices

NCT02091011
View directory record Official record
Conditions
Implantable Cardioverter Defibrillators, CRT-D Cardiac Resynchronization Therapy Defibrillator
Interventions
Not listed
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
51
States / cities
Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Nov 4, 2026, 7:03 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above

NCT06389487
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
16
States / cities
Glendale, Arizona • Phoenix, Arizona • North Hollywood, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Nov 4, 2026, 7:03 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes

NCT00306787
View directory record Official record
Conditions
Genital Herpes
Interventions
Famciclovir, Valacyclovir, Placebo matching famciclovir, Placebo matching valacyclovir
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
51
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2011 · Synced Nov 4, 2026, 7:03 AM EST
Recruiting Not applicable Interventional

Cephea Early Feasibility Study

NCT05061004
View directory record Official record
Conditions
Mitral Regurgitation
Interventions
Cephea Mitral Valve System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 4, 2026, 7:03 AM EST
Completed Phase 2Phase 3 Interventional Results available

GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease

NCT03823404
View directory record Official record
Conditions
Alzheimer Disease
Interventions
COR388 capsule, Placebo capsule
Drug
Lead sponsor
Cortexyme Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
58
States / cities
Phoenix, Arizona • Sun City, Arizona • Costa Mesa, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Nov 4, 2026, 7:03 AM EST
Not listed Not applicable Interventional

iStent Inject New Enrollment Post-Approval Study

NCT04624698
View directory record Official record
Conditions
Glaucoma, Open-Angle, Glaucoma
Interventions
iStent Inject Implantation
Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
22 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Phoenix, Arizona • Torrance, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Nov 4, 2026, 7:03 AM EST